



**HAL**  
open science

## Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts

Charlotte Legrand, L. Keller, Pierre Collinet, Anne-Laure Barbotin, Helene Behal, ChrysteLe Rubod Dit Guillet, Christine Decanter

### ► To cite this version:

Charlotte Legrand, L. Keller, Pierre Collinet, Anne-Laure Barbotin, Helene Behal, et al.. Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts. *Reproductive BioMedicine Online*, 2021, *Reproductive BioMedicine Online*, 43 (2), p. 205-214. 10.1016/j.rbmo.2021.04.020 . hal-04477131

**HAL Id: hal-04477131**

**<https://hal.univ-lille.fr/hal-04477131v1>**

Submitted on 22 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 Oocyte accumulation for Fertility Preservation in women with benign ovarian tumors (BOT)  
2 with history of previous surgery or multiple/large cysts.

3

4 **Authors:**

5 Charlotte Legrand <sup>1</sup>

6 Laura Keller <sup>2</sup>

7 Pierre Collinet <sup>3,4</sup>

8 Anne Laure Barbotin <sup>2</sup>

9 H el ene B ehal <sup>4,5</sup>

10 ChrysteLe Rubod <sup>3,4</sup>

11 Christine Decanter <sup>1,6</sup>

12 **Department affiliation :**

13 <sup>1</sup> Centre d'Assistance M edicale   la Procr eation et de Pr eservation de la Fertilit , H opital  
14 Jeanne de Flandre, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.

15 <sup>2</sup> Institut de Biologie de la Reproduction-Spermiologie-CECOS, H opital Jeanne de Flandre,  
16 Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.

17 <sup>3</sup> Service de Chirurgie Gyn ecologique, Centre Hospitalier Universitaire de Lille, F-59000  
18 Lille, France.

19 <sup>4</sup> Universit  Lille Nord de France, Facult  de M decine, F-59000 Lille, France.

20 <sup>5</sup> ULR 2694 – METRICS,  valuation des technologies de sant  et des pratiques m dicales,  
21 Centre Hospitalier Universitaire de Lille, F-59000 Lille, France.

22 <sup>6</sup> UE 4308 « Gam etog n se et qualit  du gam te »,

23 **Corresponding author:** Charlotte Legrand, Centre Hospitalier Universitaire de Lille, Avenue  
24 Eug ne Avin e, 59 000 Lille, France. *email: legrand-charlotte@live.fr*

1 **Conflict of interest:** None

2 This research did not receive any specific grant from funding agencies in the public,  
3 commercial, or not-for-profit sectors.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

1 **ABSTRACT**

2 **Research Question:** The study aimed to evaluate the relevance and the acceptance of an  
3 oocyte accumulation program in young women with benign ovarian tumor.

4 **Design:** This is a retrospective cohort study carried out in the Academic ART and Fertility  
5 Preservation Centre of the Lille University Hospital from January 2016 to December 2019.  
6 We evaluate the number of metaphase II oocytes per cycle and per patient after accumulation.  
7 We distinguished two groups for the analysis: endometrioma (“endometrioma”) and dermoid,  
8 mucinous or serous cyst (« other cysts »).

9 **Result(s):** 113 FP cycles were analysed in 70 women aged  $27.9\pm 4.8$  years. Almost all women  
10 had previous ovarian surgery before FP (89%). Mean AMH levels before COH was  $12.5\pm 8.7$   
11 pmol/L.  $6.4\pm 3.4$  total oocytes were retrieved and  $4.3\pm 3.4$  MII oocytes were vitrified per  
12 cycle. All agreed in to the oocyte accumulation program and all underwent at least 1 cycle. To  
13 date, 36 (51%) patients achieved 2 or 3 FP cycles. After accumulation,  $7.0\pm 5.23$  MII oocytes  
14 were vitrified per patient. No difference was found in terms of ovarian response and oocytes  
15 cohort between “endometrioma” and “other cysts” groups. Questionnaires after oocyte  
16 retrieval revealed abdominal bloating and mild pelvic pain in most patients with no difference  
17 according to the type of cyst. No serious adverse events occurred.

18 **Conclusion(s):** Oocyte accumulation should be systematically offered in young women with  
19 BOT whatever the histological type as it appears to be well-tolerated. Long-term follow-up is  
20 needed in order to assess the efficiency in terms of further pregnancy chances.

21

22 **Key words:** fertility preservation, oocyte vitrification, endometriomas, benign ovarian  
23 tumors.

24

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

**Key message:** Oocyte accumulation is needed to optimize the number of MII oocytes and further chances of pregnancy. FP procedures should be proposed in case of BOT, whatever the histological type.

1

## 2 INTRODUCTION

3 Ovarian cysts are observed in 10 to 20% of young women (American College of Obstetricians  
4 and Gynecologists 2007; Royal College of Obstetricians and Gynaecologists 2011; Raiga et  
5 al. 2006). 25% of them are organic cysts of which 25-35% are serous cystadenoma, 10-15%  
6 mucinous cystadenoma, 20% dermoid cyst and 20% endometrioma (American College of  
7 Obstetricians and Gynecologists 2007; Royal College of Obstetricians and Gynaecologists  
8 2011; Raiga et al. 2006). In case of large, symptomatic or progressive cysts, surgery is  
9 performed for histological examination and confirmation of benignity. Ovarian sparing  
10 surgery has become crucial for the management of ovarian tumors in children, adolescents  
11 and young women for fertility concerns. Nevertheless, the size of the tumor can be a limiting  
12 factor, as large tumors are more likely to induce oophorectomy (Legendre et al. 2014;  
13 Dunselman et al. 2014; Borghese et al. 2013; Roman et al. 2010). In addition, all these  
14 tumors, especially endometriomas (Guo 2009), are at high risk of recurrence with consequent  
15 repeat surgeries (Harada et al. 2013; Rogers, Allen, et Kives 2014; Ben-Ami et al. 2010)  
16 leading to the risk of ovarian reserve damages and further fertility impairments.

17 It is now well-established that AMH is the most reliable indicator to the ovarian follicular  
18 content (Dewailly et al. 2014). Studies of the consequences of ovarian surgery on the ovarian  
19 reserve are almost all performed in case of endometriomas. They highlighted a significant  
20 decrease of AMH levels as high as 30 to 50% after cystectomy for endometriomas (Edgardo  
21 Somigliana et al. 2012; Uncu et al. 2013; Streuli et al. 2012; Goodman et al. 2016). This  
22 decrease is maximal in cases of large tumors, bilateral tumors whatever the size, and low  
23 ovarian reserve before surgery (Goodman et al. 2016; Younis et al. 2019; Muzii et al. 2015;  
24 Coccia et al. 2011). Ovarian damages are related to the excision of healthy ovarian cortex and

1 potential vascular injury when cystectomy is performed (Alborzi et al. 2009; Matsuzaki et al.  
2 2009). In case of endometriomas, it has been shown that folliculogenesis can also be impaired  
3 due to ovarian tissue inflammation with premature follicle recruitment, higher rate of  
4 follicular atresia and alteration of the number and quality of growing follicles (Kitajima et al.  
5 2014). The impact of cystectomy in cases of cystadenomas or dermoid cysts is less obvious,  
6 except if oophorectomy is needed due to large tumor size (Rustamov et al. 2016; Mohamed et  
7 al. 2016).

8 Fertility preservation (FP) techniques are developing rapidly and must be systematically  
9 offered to women with high risk of ovarian reserve depletion. Oocyte vitrification is the first  
10 line option in the case of non-oncologic and non-emergency situations, according to the  
11 ESHRE-ASRM 2015 committee opinion (Martinez et al. 2017; Martinez 2017). It is now well  
12 established that oocyte cryopreservation is safe and efficient, with healthy babies born, thanks  
13 to the vitrification techniques (A Cobo et al. 2018; Ana Cobo et Diaz 2011; Glujovsky et al.  
14 2014; Argyle, Harper, et Davies 2016; Noyes, Porcu, et Borini 2009; Ana Cobo et al. 2014;  
15 De Munck et Vajta 2017).

16 Debates are still ongoing about FP strategies especially in endometriosis (E. Somigliana et al.  
17 2015; Donnez, García-Solares, et Dolmans 2018) and French guidelines have been recently  
18 published on this topic (C. Decanter et al. 2018). To date, there is no published data regarding  
19 oocyte vitrification for FP in case of dermoid, serous or mucinous cysts; and only three cohort  
20 studies have been published exclusively in patients with endometrioma (Ana Cobo et al.  
21 2020; Raad et al. 2018; Kim et al. 2020).

22 Because of the paucity of literature, we aimed to evaluate the relevance of an oocyte  
23 accumulation program in young women with BOT at high risk of ovarian reserve depletion  
24 due to previous surgery or presence of multiple or large cysts. The primary endpoint was to

1 evaluate the number of metaphase II (MII) oocytes eligible for vitrification after controlled  
2 ovarian hyperstimulation (COH) per cycle and after accumulation. The second endpoint was  
3 to examine the tolerance and the acceptability of the procedures in this specific population.

## 4 **MATERIALS and METHODS**

### 5 **Study design**

6 This is a retrospective analysis of collected data in the French ART registry (JFIV). This  
7 observational study was monocentric carried out in the Academic ART and Fertility  
8 Preservation Centre of the Lille University Hospital from January 2016 to December 2019.  
9 Written informed consents for both oocyte retrieval and oocyte vitrification were obtained  
10 before each procedure. The study was approved by the local ethic committee (DEC20150715-  
11 0002).

### 12 **Population**

13 Seventy patients with BOT, of which 89% had previous ovarian surgery. Large number of  
14 women have had first surgeries in other centres and sometimes years before, during childhood  
15 or adolescence. They were referred to our FP centre, because of a cyst recurrence, and/or  
16 before surgery by surgeons from the Lille University Hospital Centre.

17 Inclusion criteria were age 18 to 35, history of BOT (endometrioma, dermoid, serous or  
18 mucinous cysts) with high risk of ovarian depletion: multiple ovarian cysts, ovarian cyst  
19 larger than 5 cm of diameter, history of oophorectomy or recurrent surgeries, baseline reduced  
20 ovarian reserve. Patients had to have a social insurance and be able to give an informed  
21 consent.

22 Exclusion criteria were a diagnosis of borderline or malignant ovarian tumor, personal history  
23 of thrombo-embolic events, or undetectable AMH levels.



1 An ovarian reserve assessment was systematically carried out before COH by measuring the  
2 serum AMH level and determining the antral follicle count (AFC). AMH was measured using  
3 an automated AMH assay, Access Dxi (Beckman Coulter Immunotech®, Villepinte France).  
4 The baseline AFC was measured with a Voluson E8 Expert (General Electric  
5 Systems,VELIZY, France) with a 5–9 MHz transvaginal transducer by counting all the 2–  
6 9mm diameter follicles.

7 Up to three vitrification cycles were offered to optimize the number of MII oocytes and  
8 further chances of pregnancy (A Cobo et al. 2018).

### 9 **Controlled Ovarian Hyperstimulation (COH) protocol**

10 Agonist or antagonist protocols were used for COH. Starting r-FSH dose was determined  
11 according to patient age, body mass index (BMI) and baseline AFC and AMH, and varied  
12 from 112.5 to 450 IU/day.

13 In 88,5 % of cases, we used the fixed day 6 antagonist protocol. COH was initiated on Day 2  
14 of a spontaneous bleed. Recombinant FSH (Follitropin alpha, Gonal F®, Merck-Serono, or  
15 Follitropin beta, Puregon®, Merck USA) was administered daily until triggering and GnRh  
16 antagonist (Ganirelix, Orgalutran® 0.25mg/0.5ml MSD) was added daily on day 6.  
17 Transvaginal ultrasound examination combined with estradiol and LH measurements were  
18 performed to monitor the follicles development on day 6 of r-FSH treatment and every 2 or 3  
19 days after.

20 For the long GnRH agonist protocol, the GnRH agonist (Nafaréline, Synarel® 0.2mg/dose,  
21 pfizer) was initiated during the luteal phase of the previous cycle for pituitary down-  
22 regulation. After ultrasound examination and hormone levels measurement, r-FSH and GnRH  
23 agonist were administrated daily following the instructions previously described.

24 Triggering was achieved as soon as three follicles reached 18 mm of diameter or larger by

1 administering hCG (250 µg, Ovitrelle ®, Merck Serono) or by 0.2mg triptorelin (Decapeptyl  
2 ® Ipsen Pharma) for patients with high risk of ovarian hyperstimulation syndrome in case of  
3 antagonist protocol (Youssef et al. 2014).

#### 4 **Oocyte retrieval**

5 Oocyte retrieval was scheduled 36 to 38 hours after triggering and was performed by  
6 transvaginal ultra-sound guided needle aspiration. Two hours after oocyte retrieval, cumulus  
7 oophorus was denuded by a brief exposure to 80 IU/mL of hyaluronidase solution  
8 (Hyaluronidase Fertipro™, Belgium) followed by mechanical removal of the corona radiata  
9 with denudation pipette (Flexipet, Cook, USA) in a controlled CO<sub>2</sub> and temperature  
10 environment. Oocyte vitrification procedure was carried out after nuclear maturity assessment  
11 under stereomicroscop. Only MII oocytes were eligible for vitrification procedure.

#### 12 **Vitrification protocol**

13 We used the RapidVit Kit® (Vitrolife®, Sweden) and the closed system device RapidI®  
14 (Vitrolife®, Sweden). Vitrification procedure was performed as previously described  
15 (Christine Decanter et al. 2018). Briefly, oocytes were exposed to progressive concentrations  
16 of propanediol and ethylene glycol. Oocytes were loaded on the RapidI device in a minimum  
17 volume drop and immediately plunged into liquid nitrogen to induce vitrification and then  
18 stored at -196°C in liquid nitrogen

#### 19 **Questionnaire**

20 In accordance with our ART center policy, each patient was called back after the oocyte  
21 retrieval to answer a questionnaire regarding tolerance. They were also asked about symptoms  
22 of pelvic pain, abdominal bloating and fever. Pain intensity was assessed using a self-report  
23 scale from 0 to 10 (Numerical Scale, Echelle Numérique: EN). We have classified them into 3  
24 categories: low intensity pain ( $EN \leq 3$ ), medium intensity pain ( $4 \leq EN \leq 6$ ) and high intensity

1 pain ( $EN \geq 7$ ).

2

### 3 **Statistical analysis**

4 Categorical parameters were described as frequencies and percentages. Continuous  
5 parameters were described as means and standard deviations.

6 A generalized estimating equation (GEE) model (Poisson distribution and logit link function)  
7 taking into account the correlation between the cycles of a same patient was used to assess the  
8 associated factors with the number of MII oocytes. In the case of p-value lower than 0.10 in  
9 univariate analysis, the parameter was introduced in a multivariate model.

10 The comparison between « endometrioma » vs « other cysts » groups were performed using  
11 Chi-square test for « patient level » categorical variables, using Student t-test for « patient  
12 level » continuous variables. For « cycle level » variables, a linear mixed model with  
13 « patient » as random effect was used for dependent continuous variables; a GEE model like  
14 previously quoted for dependent count variables.

15 Data were analyzed using the SAS software (SAS Institute Inc, Cary, NC, USA) and all  
16 statistical tests were performed with a 2-tailed alpha risk of 0.05.

17

18

19

20

21

22

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## RESULTS

### Population characteristics

70 patients were referred to the Fertility Preservation Centre of the Lille University Hospital. All agreed in to the oocyte accumulation program and all underwent at least 1 cycle. 51,4% of them underwent 2 cycles and only 10,0% underwent 3 cycles.

Distribution of the different histological types of BOT in the study population is represented in Figure 1: endometrioma (n=39, [56%]), dermoid cyst (n=22, [31%]), mucinous cyst (n=5, [7%]), and serous cyst (n=4, [6%]). We distinguished 2 groups in the overall population so-called “endometrioma” (n= 39) and”other cysts” (n= 31) including dermoid, serous and mucinous cysts.

89% (n=62) of patients had a history of ovarian surgery prior to FP: cystectomy (n=36 [58%]), plasma energy ablation (n=1 [2%]), drainage (n=7 [11%]), unilateral oophorectomy (n=18 [29%]). Among these patients, 33 had a cyst recurrence of which 15 underwent a second surgery: 8 had a cystectomy on the contralateral ovary after oophorectomy, 3 had a second cystectomy and 4 had drainage secondary to a cystectomy (supplemental figure 1). 8 patients (11%) were included prior to surgical management. 32 patients (45.7 %) had a cyst during the stimulation period.

Characteristics of the patients are reported in Table 1. Mean age at accumulation program proposal was  $27.9\pm 4.8$  years. The average diameter of largest cyst was  $7.4 \pm 4.2$ cm ( $7.9 \pm 4.2$ cm in women with previous surgery and  $3.8 \pm 2.0$ cm in women with no history of surgery). Mean AMH levels was  $12.5\pm 8.7$  pmol/L and AFC was  $13.1\pm 7.9$  follicles. Twenty-nine patients (41.4%) had already low AMH levels, between 3 and 8 pmol/L, the latter being

1 our in-house threshold for predicting poor ovarian response. Thirty-six patients (51.4%) were  
2 taking oral contraceptive pill (n=32) or long agonist GnRH (n=4) before COH.

### 3 **COH outcomes and oocyte cohort**

4 Main COH outcomes are detailed in Table 2. A mean of  $6.4 \pm 3.4$  total oocytes was retrieved  
5 per cycle. The mean number of MII oocytes was  $4.3 \pm 3.4$  per cycle and of immature oocytes  
6 was  $0.6 \pm 1.0$  (germinal vesicle and immature metaphase I oocyte). Maturation rate was of  
7 66%. In 41.5% of cycles, four or fewer total oocytes were retrieved.

8 In the overall population the mean number of MII oocytes was  $7.0 \pm 5.2$  per patients after  
9 accumulation. 44.3% of them (n=31) had more than eight MII oocytes vitrified. A mean  
10 number of  $4.2 \pm 3.4$  MII oocytes was vitrified at the end of the first cycle,  $8.0 \pm 5.4$  after two  
11 cycles and  $9.4 \pm 5.6$  after three cycles (Table 2). After 1 cycle, only 15.7% of patients had 8 or  
12 more MII oocytes eligible for vitrification. After 2 or 3 cycles, 52.8% to 57.1% had more than  
13 8 MII oocytes eligible for vitrification. In 5 patients, no oocyte was eligible for vitrification  
14 after one (n=3) or two cycles (n=2). 3 of them had endometriomas, the others had dermoid  
15 and mucinous cysts. They did not have any particular characteristics at baseline and during  
16 COH. Their AMH levels were 3 pmol/L to 17.7 pmol/L.

### 17 **Associated factors with the number of MII oocytes**

18 Univariate analysis showed that AMH level (RR 1.38, 95%CI [1.17-1.62]), AFC (RR 1.40,  
19 95%CI [1.23-1.59]), estradiol level at triggering day (RR 1.19, 95%CI [1.08-1.33]) and the  
20 number of mature follicles  $\geq 15$  mm (RR 1.09, 95%CI [1.05-1.14]), had a significant positive  
21 impact on the number of MII oocytes ( $p < 0.05$ ). Conversely, BMI (RR 0.96, 95%CI [0.93-  
22 0.98]), history of oophorectomy (RR 0.65, 95%CI [0.47-0.88]), r-FSH starting dose (RR 0.72,  
23 95%CI [0.60-0.83]) and r-FSH total dose (RR 0.87, 95%CI [0.79-0.96]) were negatively  
24 associated with the number of MII oocytes ( $p < 0.05$ ). There was no effect of smoking,

1 histological type, age, taking oral contraceptive pill (OCP) before COH on the number of MII  
2 oocytes.

3 In the multivariate analysis, only the r-FSH starting dose, estradiol level and number of  
4 mature follicles  $\geq 15$  mm at triggering day remained significantly associated with the number  
5 of MII oocytes (respectively, RR[95%CI], 0.80 [0.67-0.95],  $p=0.012$ ; 1.10 [1.01-1.21],  
6  $p=0.032$ ; 1.06 [1.01-1.11],  $p=0.009$ ).

### 7 « Endometrioma » versus « other cysts »

8 We compared the two subgroups “Endometrioma” and “other cysts” (table 3). Patients with  
9 dermoid or sero-mucinous cysts were significantly younger and had a higher incidence of  
10 unilateral oophorectomy. There was no difference between the 2 groups at baseline regarding  
11 ovarian reserve indicators, smoking, BMI and taking OCP. No difference was found regarding  
12 the follicular growth under COH, neither total and MII oocytes number between the 2 groups.

### 13 Follow-up

14 Only one case of moderate ovarian hyperstimulation syndrome was reported. No infection,  
15 hemorrhagic or thromboembolic complications occurred. 100% of patients completed the  
16 questionnaire after each cycle. Questionnaires after oocyte retrieval ( $n=113$ ) revealed  
17 abdominal bloating and mild pelvic pain in most patients (figure 2). There was no difference  
18 according to the type of cyst.

19 To date, 3 patients asked for reutilization. A total of 8 MII oocytes were thawed and resulted  
20 in one live birth of a healthy baby.

21

22

23

1  
2  
3

## DISCUSSION

4 To date, this is the first cohort study interested in a systematic proposal of oocyte  
5 accumulation for FP in case of BOT whatever the histological type. These results confirmed  
6 those we previously showed in a short series of patients (Dadoun et al. 2017). Only three  
7 retrospective cohort studies have been published since on this topic but exclusively in women  
8 with endometriosis (Raad et al. 2018; Ana Cobo et al. 2020; Kim et al. 2020). Cobo *et al.*  
9 reported the results of 840 cycles performed in 485 women in their thirties, Raad *et al.* 70  
10 cycles in 49 women of same age, and Kim et al 50 cycles in 34 women before surgery with a  
11 mean number of MII oocytes per cycle of 7.2, 5.5 and 4.8 respectively (Ana Cobo et al. 2020;  
12 Raad et al. 2018; Kim et al. 2020). We reported in our overall population a mean number of  
13 4.3 MII oocytes eligible for vitrification per cycle and a mean number of 7.0 MII oocytes per  
14 patients after accumulation. These results are slightly lower than those found by Cobo *et al*  
15 and Raad *et al* despite a younger population. It must be stressed that in these two series, every  
16 types and stages of endometriosis were eligible for FP, including women with superficial  
17 lesions, absence of endometrioma or previous surgery. However, our results were similar to  
18 those of Kim et al. in patients without history of surgery. In the current study, we voluntarily  
19 focused on young patients under 35 years with high risk of ovarian function impairment due  
20 to history of repeated surgeries and/or presence of multiple or large ovarian tumors. Indeed, in  
21 our population, 89% had at least one previous ovarian surgery of which 26% had an  
22 oophorectomy, in comparison with 47% and 38% in Cobo and Raad Serie (Ana Cobo et al.  
23 2020; Raad et al. 2018). The latter reported fewer retrieved oocytes in these “post-surgery”  
24 patients, which is in agreement with our results. This is in accordance with the literature  
25 reporting ovarian damage after cystectomy for endometrioma (Edgardo Somigliana et al.  
26 2012; Uncu et al. 2013; Streuli et al. 2012; Goodman et al. 2016), but also for serous,

1 mucinous and dermoid cysts (Rustamov et al. 2016; Mohamed et al. 2016). Unfortunately, lot  
2 of patients, especially in this cohort, had their first surgeries in other centres and sometimes  
3 years before, explaining the high proportion of patients with a history of cystectomy or  
4 oophorectomy in our cohort. Surgery withhold in cases with endometrioma should be  
5 discussed and excision should be cautiously considered. Conservative treatment should be  
6 counselled as the first line of treatment, until the patient's reproductive aspirations are  
7 realized.

8 In keeping with the high incidence of previous surgery, our patients already had an  
9 impairment of their ovarian reserve: they indeed exhibited lower AMH levels than expected  
10 with a mean of  $12.5 \pm 8.7$  pmol/L, i-e,  $< -1$  Standard Deviation for age (Kelsey et al. 2011).  
11 41.4% of them had an AMH level lower to 8 pmol/l that represents our in-house cut-off  
12 threshold for predicting poor ovarian response. This indicates that these patients should have  
13 been referred to a FP centre earlier, ideally before surgery, to have more MII oocytes. Half of  
14 the population had been using OCP for at least 6 months which may have influenced the basal  
15 AMH levels (Kallio et al. 2013; Hagen et al. 2012). Nevertheless, COH while using OCP did  
16 not impact the ovarian response nor the number of MII oocytes. Interestingly, AMH levels in  
17 the multivariate analysis was no longer associated with the number of MII oocytes. In  
18 addition, if we consider results in terms of oocyte number patient by patient, a significant part  
19 (47%) with low or very low AMH levels had more than 4 total oocytes retrieved. This  
20 confirms that low AMH levels should not be an exclusion criterion before COH for FP in  
21 young patients. Maturation rate in our population of BOT was lower than expected in  
22 comparison with maturation rate in women undergoing FP for social reasons (A Cobo et al.  
23 2018; Garcia-Velasco et al. 2013; Rodriguez-Wallberg et al. 2019), and in ICSI patients in our  
24 centre (Christine Decanter et al. 2018). It has to be noted that 45,7 % of our patients had an  
25 ovarian tumor during the ovarian stimulation. One can hypothesize the existence of follicular



1 micro-environment alterations impacting the oocyte development and maturation, as it was  
2 described in case of endometriomas due to chronic inflammation (Singh et al. 2016; Sanchez  
3 et al. 2017) and in oncologic indications (Christine Decanter et al. 2018).

4 Patients from “other cysts” group were younger and had a higher incidence of oophorectomy  
5 than those in “endometrioma” group. Nevertheless, there was no statistical difference between  
6 the 2 groups regarding the follicular growth under COH and the oocyte cohort in terms of  
7 number and quality. Early referral of these young patients is recommended in order to prevent  
8 a possible risk of recurrence which would have a greater impact on their future fertility.  
9 Nevertheless, whether FP strategies should be the same in these two groups, this remains to be  
10 established in larger prospective series.

11 Rienzi *et al.* and Cobo *et al.* showed in different populations, i.e ICSI, oocyte donation or  
12 oocyte vitrification for social reasons, that the best chances of pregnancy are observed when  
13 oocyte collection is performed under 35 years old (A Cobo et al. 2018; Rienzi et al. 2012; Ana  
14 Cobo et al. 2016). They indeed reported in this age range that 8 MII oocytes may provide 30  
15 to 45% of cumulative live birth rate (A Cobo et al. 2018; Rienzi et al. 2012; Ana Cobo et al.  
16 2016). The younger the patient, the better her chances of being pregnant. In our subgroup  
17 patients with a history of recurrent surgery, the mean number of MII oocytes was too low  
18 after one cycle. Oocyte accumulation concept was primarily proposed by Cobo *et al.* in  
19 patient with low ovarian reserve in IVF procedure to increase pregnancy chances (A. Cobo et  
20 al. 2012) and is now routinely proposed in case of FP. Only  $4.3 \pm 3.4$  MII oocytes were  
21 vitrified per cycle in this study which clearly does not insure pregnancy achievement  
22 justifying the accumulation program. We indeed observed in our population a clear increase  
23 in the number of MII oocytes after accumulation, as also suggested in the cohort of Kim et al  
24 (Kim et al. 2020). Hence, if we extrapolate the recent results of Cobo *et al.* to our patients ,  
25 aged of 28, with a mean number of 7.0 MII oocytes after accumulation, they may have 30%

1 chances of live birth rate (A Cobo et al. 2018). But, it has to be stressed that these results  
2 concerned patients in an elective FP program. In the FP series in women with endometriosis,  
3 Cobo *et al* showed a cumulative live birth rate of 46,4% with an average of 9 MII oocytes per  
4 patient (Ana Cobo et al. 2020).

5 The acceptability of FP by oocyte vitrification was high as all patients agreed the procedure at  
6 the time of offer. But it is interesting to note that only 51.4% of them returned for a second  
7 cycle and 10.0% for a third one, even though in France, FP for medical reasons is completely  
8 supported by social insurance without any advance of costs. In addition, no severe adverse  
9 event occurred, and the functional tolerance was good. Logistical difficulties, and  
10 disappointment regarding the oocyte number at the first cycle were the main reasons for not  
11 coming back.

12 The retrospective design of this study with a limited number of patients does not allow us to  
13 preclude firm conclusions. Nevertheless, we analysed data prospectively collected extracted  
14 from our ART national registry, allowing us to have exhaustive and precise population  
15 description.

16 It is now too soon to evaluate the efficiency of these procedure on further fertility as only 3  
17 patients asked for re-utilization. Large prospective studies with a long-term follow-up are  
18 clearly needed to estimate the re-utilization rate, the oocyte quality through fertilization and  
19 further pregnancy rates.

20 To summarize, the results of this study highlighted that in this population of patients with  
21 history of surgeries and/or multiple or large cysts, oocyte accumulation is needed to optimize  
22 the number of MII oocytes and further chances of pregnancy. FP procedures should be offered  
23 in case of BOT, whatever the histological type, ideally before the ovarian surgery if it is  
24 technically feasible. Fertility sparing surgery remains the most challenging option in these  
25 young women until the patient's reproductive aspirations are realized.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

## BIBLIOGRAPHY

- Alborzi, Saeed, Leila Foroughinia, Perikala Vijayananda Kumar, Nasrin Asadi, et Soroosh Alborzi. 2009. « A Comparison of Histopathologic Findings of Ovarian Tissue Inadvertently Excised with Endometrioma and Other Kinds of Benign Ovarian Cyst in Patients Undergoing Laparoscopy versus Laparotomy ». *Fertility and Sterility* 92 (6): 2004-7.
- American College of Obstetricians and Gynecologists. 2007. « Management of Adnexal Masses. ACOG ». *Obstetrics and Gynecology* 110 (83): 201-14.
- Argyle, Catrin E., Joyce C. Harper, et Melanie C. Davies. 2016. « Oocyte Cryopreservation: Where Are We Now? » *Human Reproduction Update* 22 (4): 440-49.
- Ben-Ami, Ido, Noam Smorgick, Josef Tovbin, Noga Fuchs, Reuvit Halperin, et Moty Pansky. 2010. « Does Intraoperative Spillage of Benign Ovarian Mucinous Cystadenoma Increase Its Recurrence Rate? » *American Journal of Obstetrics and Gynecology* 202 (2): 142.e1-142.e5.
- Borghese, B., P. Marzouk, P. Santulli, D. de Ziegler, et C. Chapron. 2013. « Surgical treatments of presumed benign ovarian tumors ». *Journal de Gynécologie Obstétrique et Biologie de la Reproduction* 42 (8): 786-93.
- Cobo, A, J García-Velasco, J Domingo, A Pellicer, et J Remohí. 2018. « Elective and Onco-Fertility Preservation: Factors Related to IVF Outcomes ». *Human Reproduction* 33 (12): 2222-31.
- Cobo, A., Nicolás Garrido, Juana Crespo, Remohí José, et Antonio Pellicer. 2012. « Accumulation of Oocytes: A New Strategy for Managing Low-Responder Patients ». *Reproductive BioMedicine Online* 24 (4): 424-32.
- Cobo, Ana, et César Diaz. 2011. « Clinical Application of Oocyte Vitrification: A Systematic Review and Meta-Analysis of Randomized Controlled Trials ». *Fertility and Sterility* 96 (2): 277-85.
- Cobo, Ana, Juan A. García-Velasco, Aila Coello, Javier Domingo, Antonio Pellicer, et José Remohí. 2016. « Oocyte Vitrification as an Efficient Option for Elective Fertility Preservation ». *Fertility and Sterility* 105 (3): 755-64.
- Cobo, Ana, Juan Giles, Stefania Paolelli, Antonio Pellicer, José Remohí, et Juan Antonio García-Velasco. 2020. « Oocyte Vitrification for Fertility Preservation in Women with Endometriosis: An Observational Study ». *Fertility and Sterility* 113 (4): 836-44.
- Cobo, Ana, Vicente Serra, Nicolás Garrido, Inés Olmo, Antonio Pellicer, et José Remohí. 2014. « Obstetric and Perinatal Outcome of Babies Born from Vitrified Oocytes ». *Fertility and Sterility* 102 (4): 1006-1015.e4.

- 1 Coccia, M. E., F. Rizzello, G. Mariani, C. Bulletti, A. Palagiano, et G. Scarselli. 2011.  
2 « Ovarian Surgery for Bilateral Endometriomas Influences Age at Menopause ». *Human Reproduction* 26 (11): 3000-3007.  
3
- 4 Dadoun, Y., H. Azaïs, L. Keller, E. d’Orazio, P. Collinet, et C. Decanter. 2017. « Proposition  
5 systématique de préservation de la fertilité par congélation d’ovocytes en cas de  
6 tumeur ovarienne bénigne ». *Gynécologie Obstétrique Fertilité & Sénologie* 45 (6):  
7 359-65.
- 8 De Munck, Neelke, et Gábor Vajta. 2017. « Safety and Efficiency of Oocyte Vitrification ». *Cryobiology* 78 (octobre): 119-27.  
9
- 10 Decanter, C., E.M. d’Argent, J. Boujenah, C. Poncelet, C. Chauffour, P. Collinet, et P.  
11 Santulli. 2018. « Endométriose et Préservation de La Fertilité, RPC Endométriose,  
12 CNGOF-HAS ». *Gynécologie Obstétrique Fertilité & Sénologie* 46 (3): 368-72.
- 13 Decanter, Christine, Geoffroy Robin, Audrey Mailliez, Julien Sigala, Franck Morschhauser,  
14 Nassima Ramdane, Patrick Devos, Didier Dewailly, Brigitte Leroy-Martin, et Laura  
15 Keller. 2018. « Prospective Assessment of Follicular Growth and the Oocyte Cohort  
16 after Ovarian Stimulation for Fertility Preservation in 90 Cancer Patients versus 180  
17 Matched Controls ». *Reproductive BioMedicine Online* 36 (5): 543-51.
- 18 Dewailly, Didier, Claus Yding Andersen, Adam Balen, Frank Broekmans, Nafi Dilaver,  
19 Renato Fanchin, Georg Griesinger, et al. 2014. « The Physiology and Clinical Utility  
20 of Anti-Müllerian Hormone in Women ». *Human Reproduction Update* 20 (3):  
21 370-85.
- 22 Donnez, Jacques, Javier García-Solares, et Marie-Madeleine Dolmans. 2018. « Ovarian  
23 Endometriosis and Fertility Preservation: A Challenge in 2018 ». *Minerva*  
24 *Ginecologica* 70 (4): 408-14. <https://doi.org/10.23736/S0026-4784.18.04229-6>.
- 25 Dunselman, G. A. J., N. Vermeulen, C. Becker, C. Calhaz-Jorge, T. D’Hooghe, B. De Bie, O.  
26 Heikinheimo, et al. 2014. « ESHRE Guideline: Management of Women with  
27 Endometriosis ». *Human Reproduction* 29 (3): 400-412.
- 28 Garcia-Velasco, Juan A., Javier Domingo, Ana Cobo, Maria Martínez, Luis Carmona, et  
29 Antonio Pellicer. 2013. « Five Years’ Experience Using Oocyte Vitrification to  
30 Preserve Fertility for Medical and Nonmedical Indications ». *Fertility and Sterility* 99  
31 (7): 1994-99.
- 32 Glujovsky, Demián, Barbara Riestra, Carlos Sueldo, Gabriel Fiszbajn, Sjoerd Repping,  
33 Florencia Nodar, Sergio Papier, et Agustín Ciapponi. 2014. « Vitrification versus  
34 Slow Freezing for Women Undergoing Oocyte Cryopreservation ». Édité par  
35 Cochrane Gynaecology and Fertility Group. *Cochrane Database of Systematic*  
36 *Reviews* 9:CD010047.
- 37 Goodman, Linnea R., Jeffrey M. Goldberg, Rebecca L. Flyckt, Manjula Gupta, Jyoti  
38 Harwalker, et Tommaso Falcone. 2016. « Effect of Surgery on Ovarian Reserve in  
39 Women with Endometriomas, Endometriosis and Controls ». *American Journal of*  
40 *Obstetrics and Gynecology* 215 (5): 589.e1-589.e6.
- 41 Guo, S.-W. 2009. « Recurrence of Endometriosis and Its Control ». *Human Reproduction*  
42 *Update* 15 (4): 441-61.
- 43 Hagen, Casper P., Kaspar Sørensen, Richard A. Anderson, et Anders Juul. 2012. « Serum  
44 Levels of Antimüllerian Hormone in Early Maturing Girls before, during, and after  
45 Suppression with GnRH Agonist ». *Fertility and Sterility* 98 (5): 1326-30.

- 1 Harada, Miyuki, Yutaka Osuga, Asaha Fujimoto, Akihisa Fujimoto, Tomoyuki Fujii, Tetsu  
2 Yano, et Shiro Kozuma. 2013. « Predictive Factors for Recurrence of Ovarian Mature  
3 Cystic Teratomas after Surgical Excision ». *European Journal of Obstetrics &  
4 Gynecology and Reproductive Biology* 171 (2): 325-28.
- 5 Kallio, Sanna, Johanna Puurunen, Aimo Ruokonen, Tommi Vaskivuo, Terhi Piltonen, et Juha  
6 S. Tapanainen. 2013. « Antimüllerian Hormone Levels Decrease in Women Using  
7 Combined Contraception Independently of Administration Route ». *Fertility and  
8 Sterility* 99 (5): 1305-10.
- 9 Kelsey, Thomas W., Phoebe Wright, Scott M. Nelson, Richard A. Anderson, et W. Hamish B  
10 Wallace. 2011. « A Validated Model of Serum Anti-Müllerian Hormone from  
11 Conception to Menopause ». *PLoS ONE* 6 (7).
- 12 Kim, Se Jeong, Seul Ki Kim, Jung Ryeol Lee, Chang Suk Suh, et Seok Hyun Kim. 2020.  
13 « Oocyte Cryopreservation for Fertility Preservation in Women with Ovarian  
14 Endometriosis ». *Reproductive BioMedicine Online* 40 (6): 827-34.
- 15 Kitajima, Michio, Marie-Madeleine Dolmans, Olivier Donnez, Hideaki Masuzaki, Michelle  
16 Soares, et Jacques Donnez. 2014. « Enhanced Follicular Recruitment and Atresia in  
17 Cortex Derived from Ovaries with Endometriomas ». *Fertility and Sterility* 101 (4):  
18 1031-37.
- 19 Legendre, Guillaume, Laurent Catala, Catherine Morinière, Céline Lacoeyille, Françoise  
20 Bousson, Loïc Sentilhes, et Philippe Descamps. 2014. « Relationship between  
21 Ovarian Cysts and Infertility: What Surgery and When? » *Fertility and Sterility* 101  
22 (3): 608-14.
- 23 Martinez, Francisca. 2017. « Update on Fertility Preservation from the Barcelona  
24 International Society for Fertility Preservation–ESHRE–ASRM 2015 Expert Meeting:  
25 Indications, Results and Future Perspectives†‡ ». *Human Reproduction* 32 (9):  
26 1802-11.
- 27 Martinez, Francisca, Claus Yding Andersen, P.N. Barri, Robert Brannigan, A. Cobo, Jacques  
28 Donnez, Marie Madeleine Dolmans, et al. 2017. « Update on Fertility Preservation  
29 from the Barcelona International Society for Fertility Preservation–ESHRE–ASRM  
30 2015 Expert Meeting: Indications, Results and Future Perspectives ». *Fertility and  
31 Sterility* 108 (3): 407-415.e11..
- 32 Matsuzaki, S., C. Houle, C. Darcha, J.-L. Pouly, G. Mage, et M. Canis. 2009. « Analysis of  
33 Risk Factors for the Removal of Normal Ovarian Tissue during Laparoscopic  
34 Cystectomy for Ovarian Endometriosis ». *Human Reproduction* 24 (6): 1402-6.
- 35 Mohamed, Ahmed A., Tarek K. Al-Hussaini, Mohamed M. Fathalla, Tarek T. El Shamy,  
36 Ibrahim I. Abdelaal, et Saad A. Amer. 2016. « The Impact of Excision of Benign  
37 Nonendometriotic Ovarian Cysts on Ovarian Reserve: A Systematic Review ».  *38 American Journal of Obstetrics and Gynecology* 215 (2): 169-76.
- 39 Muzii, Ludovico, Chiara Achilli, Francesca Lecce, Antonella Bianchi, Silvia Franceschetti,  
40 Claudia Marchetti, Giorgia Perniola, et Pierluigi Benedetti Panici. 2015. « Second  
41 Surgery for Recurrent Endometriomas Is More Harmful to Healthy Ovarian Tissue  
42 and Ovarian Reserve than First Surgery ». *Fertility and Sterility* 103 (3): 738-43.
- 43 Noyes, N, E Porcu, et A Borini. 2009. « Over 900 Oocyte Cryopreservation Babies Born with  
44 No Apparent Increase in Congenital Anomalies ». *Reproductive BioMedicine Online*  
45 18 (6): 769-76.

- 1 Raad, Jade, Charlotte Sonigo, Chloé Tran, Christophe Sifer, Isabelle Cedrin Durnerin, et  
2 Michaël Grynberg. 2018. « Oocyte Vitrification for Preserving Fertility in Patients  
3 with Endometriosis: First Observational Cohort Study... and Many Unresolved  
4 Questions. Letter to the Editor ». *European Journal of Obstetrics & Gynecology and  
5 Reproductive Biology* 220 (janvier): 140-41.
- 6 Raiga, J., R. Djafer, B. Benoit, et A. Treisser. 2006. « Management of ovarian cysts ». *Journal de Chirurgie* 143 (5): 278-84.
- 8 Rienzi, L., A. Cobo, A. Paffoni, C. Scarduelli, A. Capalbo, G. Vajta, J. Remohi, G. Ragni, et  
9 F. M. Ubaldi. 2012. « Consistent and Predictable Delivery Rates after Oocyte  
10 Vitrification: An Observational Longitudinal Cohort Multicentric Study ». *Human  
11 Reproduction* 27 (6): 1606-12.
- 12 Rodriguez-Wallberg, Kenny A., Anna Marklund, Frida Lundberg, Ida Wikander, Milan  
13 Milenkovic, Amandine Anastacio, Fotios Sergouniotis, et al. 2019. « A Prospective  
14 Study of Women and Girls Undergoing Fertility Preservation Due to Oncologic and  
15 Non-Oncologic Indications in Sweden—Trends in Patients’ Choices and Benefit of the  
16 Chosen Methods after Long-Term Follow Up ». *Acta Obstetrica et Gynecologica  
17 Scandinavica* 98 (5): 604-15.
- 18 Rogers, Erin M., Lisa Allen, et Sari Kives. 2014. « The Recurrence Rate of Ovarian Dermoid  
19 Cysts in Pediatric and Adolescent Girls ». *Journal of Pediatric and Adolescent  
20 Gynecology* 27 (4): 222-26.
- 21 Roman, H., O. Tarta, I. Pura, I. Opris, N. Bourdel, L. Marpeau, et J. C. Sabourin. 2010.  
22 « Direct Proportional Relationship between Endometrioma Size and Ovarian  
23 Parenchyma Inadvertently Removed during Cystectomy, and Its Implication on the  
24 Management of Enlarged Endometriomas ». *Human Reproduction* 25 (6): 1428-32.
- 25 Royal College of Obstetricians and Gynaecologists. 2011. « Management of Adnexal Masses  
26 in Premenopausal Women, RCOG, Green Top Guidelines, London, UK ».
- 27 Rustamov, Oybek, Monica Krishnan, Stephen A Roberts, et Cheryl T Fitzgerald. 2016.  
28 « Effect of Salpingectomy, Ovarian Cystectomy and Unilateral Salpingo-  
29 Oophorectomy on Ovarian Reserve ». *Gynecological Surgery* 13 (3): 173-78.
- 30 Sanchez, Ana Maria, Valeria Stella Vanni, Ludovica Bartiromo, Enrico Papaleo, Eran  
31 Zilberberg, Massimo Candiani, Raoul Orvieto, et Paola Viganò. 2017. « Is the oocyte  
32 quality affected by endometriosis? A review of the literature ». *Journal of Ovarian  
33 Research* 10 (1): 43.
- 34 Singh, Abhay Kumar, Mainak Dutta, Ratna Chattopadhyay, Baidyanath Chakravarty, et Koel  
35 Chaudhury. 2016. « Intrafollicular interleukin-8, interleukin-12, and adrenomedullin  
36 are the promising prognostic markers of oocyte and embryo quality in women with  
37 endometriosis ». *Journal of Assisted Reproduction and Genetics* 33 (10): 1363-72.
- 38 Somigliana, E., P. Viganò, F. Filippi, E. Papaleo, L. Benaglia, M. Candiani, et P. Vercellini.  
39 2015. « Fertility Preservation in Women with Endometriosis: For All, for Some, for  
40 None? » *Human Reproduction* 30 (6): 1280-86.
- 41 Somigliana, Edgardo, Nicola Berlanda, Laura Benaglia, Paola Viganò, Paolo Vercellini, et  
42 Luigi Fedele. 2012. « Surgical Excision of Endometriomas and Ovarian Reserve: A  
43 Systematic Review on Serum Antimüllerian Hormone Level Modifications ». *Fertility  
44 and Sterility* 98 (6): 1531-38.
- 45 Streuli, I., D. de Ziegler, V. Gayet, P. Santulli, G. Bijaoui, J. de Mouzon, et C. Chapron. 2012.

1 « In Women with Endometriosis Anti-Mullerian Hormone Levels Are Decreased Only  
2 in Those with Previous Endometrioma Surgery ». *Human Reproduction* 27 (11):  
3 3294-3303.

4 Uncu, G., I. Kasapoglu, K. Ozerkan, A. Seyhan, A. Oral Yilmaztepe, et B. Ata. 2013.  
5 « Prospective Assessment of the Impact of Endometriomas and Their Removal on  
6 Ovarian Reserve and Determinants of the Rate of Decline in Ovarian Reserve ».  
7 *Human Reproduction* 28 (8): 2140-45.

8 Younis, Johnny S., Nora Shapso, Richard Fleming, Izhar Ben-Shlomo, et Ido Izhaki. 2019.  
9 « Impact of Unilateral versus Bilateral Ovarian Endometriotic Cystectomy on Ovarian  
10 Reserve: A Systematic Review and Meta-Analysis ». *Human Reproduction Update* 25  
11 (3): 375-91.

12 Youssef, Mohamed AFM, Fulco Van der Veen, Hesham G. Al-Inany, Monique H. Mochtar,  
13 Georg Griesinger, Mohamed Nagi Mohesen, Ismail Aboufoutouh, et Madelon van  
14 Wely. 2014. « Gonadotropin-releasing Hormone Agonist versus HCG for Oocyte  
15 Triggering in Antagonist-assisted Reproductive Technology ». *Cochrane Database of*  
16 *Systematic Reviews* 10:CD008046.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13

14 **LEGENDS of FIGURES**

15 Figure 1: histological types of BOT

16 Figure 2: Tolerance questionnaire result

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13

| <b>Table 1 : Population characteristics</b> |                              |
|---|------------------------------|
| <b>Characteristics</b>                      | <b>Values (n = 70)</b>       |
| Age (years)                                 | 27.9±4.8<br>28.0 [18.0-35.0] |
| Smoking <sup>a</sup>                        | 23/70 (33.3)                 |
| Ovaries number                              |                              |
| 1   | 18/70 (25.7)                 |
| 2   | 52/70 (74.3)                 |
| Mean number of surgeries                    | 1.2±0.75<br>1.0 [0-2.0]      |
| Diameter of largest cyst (cm)               | 7.4 ± 4.2<br>6.8 [2.0-20.0]  |
| Contraception                               |                              |
| No  | 34/70 (48.6)                 |
| Yes   | 36/70 (51.4)                 |
| Number of FP cycles                         |                              |
| 1   | 34/70 (48.6)                 |
| 2   | 29/70 (41.4)                 |
| 3   | 7/70 (10.0)                  |
| Body Mass Index (kg/m <sup>2</sup> )        | 24.3±5.6<br>22.9 [17.0-42.7] |
| Total AFC                                   | 13.1±7.9<br>12.0 [4.0-36.0]  |
| AMH (pmol/L)                                | 12.5±8.7<br>9.6 [3.0-43.0]   |
| AMH ≤ 8 pmol/L                              | 29/70 (41.4)                 |

14  
15  
16  
17  
18  
19  
20  
21  
22  
23

Values are expressed as mean ± standard deviation and median [mini-maxi], or number (percentage).

<sup>a</sup> 1 missing data

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14

| <b>Table 2 : COH outcomes</b>                          |                                    |
|--|------------------------------------|
| <b>Parameters per cycle (n=113)</b>                    | <b>Value</b>                       |
| Protocol   |                                    |
| antagonist   | 100/113 (88.5)                     |
| agonist  | 13/113 (11.5)                      |
| Recombinant FSH starting dose (UI)                     | 306.5±101.6<br>300.0 [112.5-450.0] |
| Recombinant FSH cumulative dose (UI)                   | 3319±1441<br>3000 [675.0-9000]     |
| Duration of ovarian stimulation (days)                 | 10.6±2.1<br>10.0 [5.0-18.0]        |
| Oestradiol level at triggering day (ng/ml)             | 1270±1088<br>874.0 [173.0-6654]    |
| Triggering   |                                    |
| hCG (250 µg, Ovitrelle)                                | 101/113 (89.4)                     |
| 0.2 mg triptorelin                                     | 12/113 (10.6)                      |
| Number of follicles ≥15mm                              | 6.4±3.4<br>6.0 [1.0-19.0]          |
| Number of MII oocytes                                  | 4.3 ± 3.4<br>6.0 [0-19.0]          |
| Number of MII oocytes/ Total oocytes : maturation rate | 482/724 (66.6)                     |
| Number of MII oocytes/ Number of follicles ≥ 15mm      | 0.7 ± 0.6<br>0.7 [0-2.5]           |
| Low ovarian response ≤ 4 total oocytes                 | 47/113 (41.5)                      |
| <b>Parameters per patient (n=70)</b>                   |                                    |
| Number of MII oocytes / patient after accumulation     | 7.0 ± 5.2<br>6.0 [0-22.0]          |
| Number of MII oocytes after 1 cycle                    | 4.2 ± 3.4<br>3.0 [0-16.0]          |
| Number of MII oocytes after 2 cycles                   | 8.0 ± 5.4<br>9.0 [0-22.0]          |
| Number of MII oocytes after 3 cycles                   | 9.4 ± 5.6<br>9.0 [3.0-18.0]        |
| ≥ 8 MII oocytes  | 31/70 (44.3)                       |

Values are expressed as mean  $\pm$  standard deviation and median [mini-maxi], or number (percentage)

| <b>Table 3 : Comparison « endometrioma » versus « other cysts »</b> |                       |                              |                |
|---|-----------------------|------------------------------|----------------|
|   | <b>Other<br/>N=31</b> | <b>Endometrioma<br/>N=39</b> | <b>p value</b> |
| Age (years)   | 25.8 $\pm$ 4.4        | 29.5 $\pm$ 4.6               | 0,001          |
| Smoking   | 12 (40)               | 11 (28.2)                    | 0.30           |
| Ovaries number :  |                       |                              |                |
| 1   | 16 (51.6)             | 2 (5.1)                      | 0.001          |
| 2   | 15 (48.4)             | 37 (94.9)                    |                |
| BMI (kg/m <sup>2</sup> )  | 24.6 $\pm$ 6          | 24.2 $\pm$ 5.5               | 0.77           |
| AMH (pmol/L)  | 12.7 $\pm$ 9          | 12.3 $\pm$ 8.5               | 0.85           |
| AFC   | 13.6 $\pm$ 7.6        | 12.8 $\pm$ 8.2               | 0.73           |
| Contraception :   |                       |                              |                |
| Yes   | 13 (41.9)             | 23 (59.0)                    | 0.16           |
| No  | 18 (58.1)             | 16 (41.0)                    |                |
| r-FSH starting dose <sup>a</sup>                                    | 309.2 $\pm$ 97.7      | 304.5 $\pm$ 105.3            | 0.78           |
| r-FSH cumulative dose <sup>a</sup>                                  | 3597 $\pm$ 1725       | 3105 $\pm$ 1149              | 0,097          |
| Duration of ovarian stimulation <sup>a</sup>                        | 10.9 $\pm$ 2.3        | 10.3 $\pm$ 1.9               | 0.17           |
| E2 level at triggering day <sup>a</sup>                             | 1139 $\pm$ 1167       | 1369 $\pm$ 1021              | 0.18           |
| Number of follicle $\geq$ 15mm <sup>a</sup>                         | 6.8 $\pm$ 4,0         | 6.0 $\pm$ 2.8                | 0.25           |
| Total oocytes <sup>a</sup>  | 7.3 $\pm$ 4.9         | 5.8 $\pm$ 3.8                | 0.11           |
| MII oocytes <sup>a</sup>  | 4.8 $\pm$ 3.9         | 3.9 $\pm$ 3.1                | 0.18           |
| Maturation rate <sup>a</sup>  | 233/356 (65.4)        | 249/368 (67.7)               | 0.58           |

Values are expressed as mean  $\pm$  standard deviation or number (percentage)

<sup>a</sup> Values are calculated over all cycles (n=49 cycles for « other » group, n=64 cycles for « endometrioma »).







Figure 1



EN ≤ 3: low intensity pain,  
 4 ≤ EN ≤ 6: medium intensity pain,  
 EN ≥ 7: high intensity pain

Figure 2